Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 810-200-7 | CAS number: 1050477-45-6
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
No studies are availabe for Carboxy-TH-naphthyridin (CAS No. 1050477-45-6). According to expert opinion a (weaker) pharmacological action of the compound cannot be ruled out due to the structural similarity to the active pharmaceutical ingredient (API; CAS No. 1050477-31-0). As the major findings of the toxicological studies with the API were considered to be related to its pharmacological action (selective, non steroidal mineralocorticoid receptor (MR) antagonist) a similar tolerability of the precursor is to be assumed. Although no in vitro assays, which reveal that Carboxy-TH-naphthyridin acts as (MR) antagonist, are available.
As part of the program of nonclinical studies for the development and registration of pharmaceuticals for human use several toxicological studies with repeated oral exposure up to 26 weeks (rat) and 39 weeks (dog) are available for the API. In these studies significant toxic effects, of relevance for human health , on kidney and adrenal were produced at 15 mg/kg (male rat)/5 mg/kg (female rat) and 1.5 mg/kg (male dog). For the female dog the high dose level of 5 mg/mg corresponds to the NOAEL. Therefore the API was allocated to STOT RE Category 2 (primary target organs of toxicity = kidney and adrenal).
Justification for classification or non-classification
According to the corresponding active pharmaceutical ingredient (CAS No. 1050477-31-0) the substance is classified in STOT RE Category 2 (primary target organs of toxicity = kidney and adrenal)
.Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
